
This past week, we reached a milestone that is nothing short of extraordinary. Our very first patients received the Ocumetics Accommodating Intraocular Lens. Just one week later, they are recovering well—and importantly, no complications have been observed.
I cannot overstate how meaningful this moment is. For years, we have poured our hearts, energy, and belief into making the Ocumetics Lens a reality. To now see it safely implanted and beginning to change lives is remarkable. These are the moments we dreamed of.
The early signs are encouraging and give us confidence as we move forward with the next surgical day and complete the first group of patients. The real test lies ahead, as healing continues and vision outcomes begin to emerge.
This achievement is proof that bold ideas, relentless effort, and true teamwork can change the world. And make no mistake—we are changing the world.
Thank you for believing. Thank you for persevering. And thank you for standing shoulder to shoulder with us on this journey. Together, we are making history.
With pride and gratitude,
Dean Burns
President, CEO and Director
Ocumetics Technology
Calgary, AB – TheNewswire – January 2, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QB0) is pleased to announce that it has closed the first tranche of its previously announced best efforts brokered private placement of units of the Company (the “Units”) for aggregate gross proceeds of approximately
Calgary, AB – TheNewswire – December 19, 2025 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QB0) announces that further to its previously announced (November 25, 2025) brokered private placement (the “Offering”) on a best-efforts basis led by Centurion One Capital Corp. (the “Lead Agent”), the Corporation has amended the
Calgary, Alberta – TheNewswire – December 9, 2025 – Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, is pleased to announce that Medicel AG (“Medicel”), a global leader in ophthalmic device delivery systems, has further modified its lens delivery technology in response to




